

CONTENTS

FOREWORD	9
ACKNOWLEDGEMENT	11
I. ACID-BASE EQUILIBRIUM AND ITS MOST COMMON DISORDERS (<i>Martin Vejražka</i>)	13
1 Buffer systems	13
1.1 Hydrogen carbonate buffer	13
2 Regulation of physiological and metabolic processes	14
2.1 Respiration	14
2.2 Renal regulation of ABE	15
3 Selected parameters used in the diagnosis of acid-base balance disorders	16
3.1 pH of whole blood	16
3.2 Partial pressure of carbon dioxide (pCO ₂)	16
3.3 Concentration of hydrogen carbonates	17
3.4 Base excess	17
4 The most common causes of metabolic acidosis	18
4.1 Metabolic acidosis caused by increase of the concentration of relatively strong anions	18
4.2 Metabolic acidosis from loss of hydrogen carbonate	20
5 The most common causes of metabolic alkalosis	20
6 Respiratory disorders	21
7 Relationship between acid-base balance and ion metabolism	21
7.1 Exchange of K ⁺ and H ⁺ on cell membranes	21
7.2 Competition between Ca ²⁺ and H ⁺ for protein binding sites	22
7.3 Paradoxic aciduria	22
II. PATHOBIOCHEMISTRY OF INFLAMMATION (<i>Marta Kalousová</i>)	23
1 Signs of inflammation	23
2 Mediators of inflammation	24
3 Cells involved in inflammation and phagocytosis	26
4 Acute phase reactants	27
5 Immunoglobulins	28
6 Metabolic changes during inflammation	29
7 Clinical significance	29
III. REACTIVE OXYGEN SPECIES IN THE BODY. OXIDATIVE DAMAGE AND ANTIOXIDANT DEFENSE (<i>Jan Pláteník</i>)	31
1 Oxygen in the body	31
2 Sources and properties of the major reactive species	33
2.1 Singlet oxygen	34
2.2 Superoxide radical	34
2.3 Hydrogen peroxide	36

2.4	Hydroxyl radical	36
2.5	Hypochlorous acid	37
2.6	Nitric oxide	38
3	Oxidative damage to biomolecules	40
3.1	Lipid peroxidation	40
3.2	Oxidative damage to proteins	42
3.3	Oxidative damage to DNA	44
4	Antioxidant defense	47
4.1	Anatomical arrangement	47
4.2	Antioxidant enzymes	48
4.3	Sequestration of redox-active transition metals	51
4.4	Low-molecular-weight antioxidants	54
4.4.1	Diet-derived antioxidants	54
4.4.2	Endogenous antioxidant substrates	57
4.5	Stress response and regulated cell death	58
5	Beneficial effects of reactive species – some examples	59
5.1	Enzyme active centers	59
5.2	Phagocyte weapons	61
5.3	Redox signaling	63
6	Oxidative stress in human pathology	66

IV. ADVANCED GLYCATION END-PRODUCTS. NON-ENZYMATIC GLYCATION AND CARBONYL STRESS (*Marta Kalousová*)

1	Basic characteristics of AGEs	69
2	Pathways of AGEs formation and metabolism	69
3	Determination of AGEs	72
4	The effect of AGEs in the organism	72
5	Clinical significance of AGEs	73
6	Possibilities to decrease AGE-levels	74

V. METABOLIC SYNDROME (*Marek Vecka*)

1	Epidemiology and underlying causes of metabolic syndrome	77
2	Definition	78
3	Pathogenesis of metabolic syndrome	78
3.1	Insulin resistance	79
3.1.1	Mechanism of insulin resistance	80
3.1.2	Hyperglycemia-induced toxic pathways	83
3.2	Neurohumoral activation	84
3.2.1	Role of adipokines	84
3.2.2	Renin-angiotensin-aldosterone system	86
3.2.3	Hyperactivation of sympathetic neuronal system (SNS) in MetS	87
3.2.4	Myokines	88
3.3	Chronic low-grade inflammation in MetS	88
3.3.1	Role of oxidative stress in metabolic syndrome	88
3.3.2	Abdominal obesity and inflammatory state	90
3.3.3	Pro-thrombotic state	91
4	Energy dysbalance	91
4.1	Overnutrition	91
4.1.1	High fat intake	91
4.1.2	High sugar intake	92
4.1.3	Dyslipidemia of MetS	94
4.1.4	Microbiome	94
4.2	Obesity without MetS vs. MetS without obesity	97
5	Genetics of metabolic syndrome	97
5.1	Association of MetS with candidate genes	98
5.2	Linkage studies for MetS	98
5.3	Genome-wide association studies	98

VI. ATHEROSCLEROSIS – MAIN PATHOBIOCHEMICAL PROCESSES INVOLVED	
IN THE FORMATION OF ATHEROSCLEROTIC PLAQUE (<i>Lenka Fialová</i>)	101
1 Stages of atherosclerosis	101
2 Lipoproteins in atherosclerosis	102
2.1 Low-density lipoproteins	102
2.2 High-density lipoproteins	103
3 The important pathogenic processes in the development of atherosclerosis	103
4 Endothelial dysfunction	104
5 Lipoproteins entry into the vessel intima	104
6 Modification of LDL particles	104
6.1 Oxidized LDL	105
6.2 Glycated LDL	105
6.3 Carbamoylated LDL	106
6.4 Atherogenic properties of modified LDL	107
7 Monocyte recruitment into intima	108
8 Foam cell formation	108
8.1 Scavenger receptor class A – SR-A1 and SR-A2	110
8.2 Scavenger receptor class B – CD36	110
8.3 Scavenger receptor class B – SR-B1	110
9 Smooth muscle cell proliferation and production of extracellular matrix	111
10 Atherosclerotic plaque destabilization	111
11 Atheroprotective functions of high-density lipoproteins	112
11.1 Reverse cholesterol transport	112
11.2 Antioxidative effects	113
11.3 Anti-inflammatory effects	113
11.4 Vasodilatory and anti-thrombotic effects	113
11.5 Dysfunctional HDL	114
VII. ISCHEMIA / REPERFUSION INJURY TO THE HEART (<i>Jan Pláteník</i>)	117
1 Metabolic alteration due to hypoxia/ischemia	117
1.1 Limits of energy production	117
1.2 Catabolism of adenine nucleotides	118
1.3 Reverse action of ATP synthase	120
1.4 Myoglobin and nitric oxide	122
1.5 Acidosis	123
1.6 Disruption of ion gradients	126
2 Reperfusion injury	129
2.1 Calcium dysregulation	130
2.2 Oxidative stress	131
2.3 Mitochondrial permeability transition (MPT)	133
3 Ischemic preconditioning (IPC)	135
VIII. PROTEIN FOLDING (<i>Jiří Jonák</i>)	139
1 Introduction	139
2 Protein folding process	140
3 Repetitive regular secondary structure elements of proteins	143
4 Water and the hydrophobic effect	147
5 Folding pathways	151
6 Protein conformational stability	154
6.1 Electrostatic forces	154
6.2 Hydrophobic forces	156
6.3 Disulfide bonds	157
6.4 Limits to protein stability	157
7 Folding accessory proteins	158
7.1 Molecular chaperones	159
7.2 Protein disulfide isomerases	162
7.3 Peptidyl prolyl <i>cis-trans</i> isomerases – immunophilins	163

IX. DISEASES ASSOCIATED WITH MISFOLDING AND ALTERNATIVE FOLDING OF PROTEINS. PRIONS (<i>Jiří Jonák</i>)	166
1 Protein degradation due to incorrect folding caused by mutation(s) leading to disease	166
2 Protein/peptide aggregation into oligomers and fibrils leading to disease. Aggregation diseases	168
2.1 Protein aggregation due to mutation	170
2.1.1 Sickle cell anemia	170
2.1.2 Systemic amyloidoses	170
2.2 Peptide/protein aggregation due to imbalance in its turnover	171
2.2.1 Alzheimer's disease	171
2.2.2 Other neurodegenerative diseases with protein aggregations	178
2.3 Protein aggregation due to protein intrinsic susceptibility to alternative folding/misfolding. Prion diseases	180
2.3.1 Hypothetical pathogenesis of prion diseases	183
2.3.2 Forms of CJD and variations in the genotype at codon 129	185
2.3.3 Animal prion diseases	185
2.3.4 Infectious forms of CJD	186
2.3.5 Prion infection pathways	188
2.3.6 Prion detection methods	189
2.3.7 Late-onset of inherited prion diseases	190
2.3.8 Properties of PrP ^C and PrP ^{Sc}	190
2.4 Prions in other neurodegenerative diseases?	191
2.5 Prion-like aggregates associated with physiological functions	192
X. AGEING (<i>Jan Pláteník</i>)	195
1 Average life expectancy and maximum lifespan	195
2 Biochemical mechanisms of ageing	196
2.1 Oxidative stress	197
2.2 Glycations	198
2.3 Mitochondrial dysfunction	201
2.4 Alteration of nuclear DNA	203
2.5 Telomeres and cellular senescence	206
2.6 Alteration of epigenome	209
2.7 Collapse of proteostasis	211
2.8 Inflammageing	213
3 The ultimate limits	215
4 Evolution of ageing	216
4.1 Selection shadow	216
4.2 Theory of antagonistic pleiotropy	216
4.3 Disposable soma theory	217
5 Life-style interventions	217
5.1 Antioxidants	217
5.2 Caloric restriction	218
5.3 Physical exercise	220
XI. ALCOHOL METABOLISM AND ITS CONSEQUENCES FOR ORGANISM DAMAGE (<i>Tomáš Zima</i>)	224
1 Metabolism of alcohol	224
2 Tissue and organ damage by alcohol	227
2.1 Liver damage	228
2.2 Cardiovascular diseases	229
2.3 Cancer	230
2.4 Nervous system	230
3 Alcohol abuse – a global problem	231
LIST OF ABBREVIATIONS	235